Details
Title
Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research
Author
Erdemli, Gül 1
; Grammatikopoulou, Margarita 2 ; Wagner, Bertil 3 ; Vairavan, Srinivasan 3
; Curcic, Jelena 4
; Aarsland, Dag 5
; Wittenberg, Gayle 3
; Nikolopoulos, Spiros 2 ; Muurling, Marijn 6 ; Froehlich, Holger 7
; de Boer, Casper 6 ; Shanbhag, Niraj M. 8 ; Nies, Vera J. M. 9 ; Coello, Neva 10
; Gove, Dianne 11 ; Diaz, Ana 11 ; Foy, Suzanne 12 ; Dartee, Wim 10 ; Brem, Anna-Katharine 13
1 Novartis Pharmaceuticals Corporation, Cambridge, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056)
2 Centre for Research & Technology Hellas, Information Technologies Institute, Thessaloniki, Greece (GRID:grid.423747.1) (ISNI:0000 0001 2216 5285)
3 LLC, a Johnson & Johnson company, Janssen Research & Development, Titusville, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
4 Novartis, Biomedical Research, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
5 Stavanger University Hospital, Centre for Age-Related Medicine, Stavanger, Norway (GRID:grid.412835.9) (ISNI:0000 0004 0627 2891); King’s College London, Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
6 Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Alzheimer Center Amsterdam, Neurology, Amsterdam, The Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X); Neurodegeneration, Amsterdam Neuroscience, Amsterdam, The Netherlands (GRID:grid.484519.5)
7 Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Department of Bioinformatics, Sankt Augustin, Germany (GRID:grid.418688.b) (ISNI:0000 0004 0494 1561); Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn-Aachen International Center for IT, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
8 Inc, Takeda Development Center Americas, Lexington, USA (GRID:grid.419849.9) (ISNI:0000 0004 0447 7762)
9 Foundation Lygature, Utrecht, The Netherlands (GRID:grid.491493.2)
10 Novartis Pharma AG, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
11 Alzheimer Europe, Luxembourg, Luxembourg (GRID:grid.424021.1) (ISNI:0000 0001 0739 010X)
12 a Johnson & Johnson company, Janssen Research & Development UK, High Wycombe, UK (GRID:grid.507827.f)
13 King’s College London, Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); University of Bern, University Hospital of Old Age Psychiatry, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
; Grammatikopoulou, Margarita 2 ; Wagner, Bertil 3 ; Vairavan, Srinivasan 3
; Curcic, Jelena 4
; Aarsland, Dag 5
; Wittenberg, Gayle 3
; Nikolopoulos, Spiros 2 ; Muurling, Marijn 6 ; Froehlich, Holger 7
; de Boer, Casper 6 ; Shanbhag, Niraj M. 8 ; Nies, Vera J. M. 9 ; Coello, Neva 10
; Gove, Dianne 11 ; Diaz, Ana 11 ; Foy, Suzanne 12 ; Dartee, Wim 10 ; Brem, Anna-Katharine 13
1 Novartis Pharmaceuticals Corporation, Cambridge, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056)
2 Centre for Research & Technology Hellas, Information Technologies Institute, Thessaloniki, Greece (GRID:grid.423747.1) (ISNI:0000 0001 2216 5285)
3 LLC, a Johnson & Johnson company, Janssen Research & Development, Titusville, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
4 Novartis, Biomedical Research, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
5 Stavanger University Hospital, Centre for Age-Related Medicine, Stavanger, Norway (GRID:grid.412835.9) (ISNI:0000 0004 0627 2891); King’s College London, Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
6 Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Alzheimer Center Amsterdam, Neurology, Amsterdam, The Netherlands (GRID:grid.16872.3a) (ISNI:0000 0004 0435 165X); Neurodegeneration, Amsterdam Neuroscience, Amsterdam, The Netherlands (GRID:grid.484519.5)
7 Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Department of Bioinformatics, Sankt Augustin, Germany (GRID:grid.418688.b) (ISNI:0000 0004 0494 1561); Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn-Aachen International Center for IT, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
8 Inc, Takeda Development Center Americas, Lexington, USA (GRID:grid.419849.9) (ISNI:0000 0004 0447 7762)
9 Foundation Lygature, Utrecht, The Netherlands (GRID:grid.491493.2)
10 Novartis Pharma AG, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
11 Alzheimer Europe, Luxembourg, Luxembourg (GRID:grid.424021.1) (ISNI:0000 0001 0739 010X)
12 a Johnson & Johnson company, Janssen Research & Development UK, High Wycombe, UK (GRID:grid.507827.f)
13 King’s College London, Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); University of Bern, University Hospital of Old Age Psychiatry, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
Pages
232
Publication year
2024
Publication date
Dec 2024
e-ISSN
23986352
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3100711558
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.